Primary Radiation Therapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer

Official Title

A Randomized Trial of Treatment De-Escalation for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiation Therapy vs. Trans-Oral Surgery (ORATOR II)

Summary:

The goal of this randomized treatment de-escalation study is to formally compare outcomes in HPV related oropharyngeal cancer tumours treated with a primary radiation therapy versus a primary surgical approach, to provide a high level of evidence to guide the selection of treatment options for a subsequent phase III trial

Trial Description

Primary Outcome:

  • 2 year progression free survival (comparison with historical controls)
Secondary Outcome:
  • Quality of Life 1 year post treatment
  • Overall Survival
  • Quality of life
  • Quality of life
  • Quality of life
  • Quality of life
  • Quality of life
  • Quality of life
  • toxicity profile of both study arms using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 4
  • Feeding tube rate at 1 year
  • CTCAE Dysphagia grade
  • Speech intelligibility
  • Normalcy of diet
  • 2 year progression-free survival comparison between Arm 1 and Arm 2
The goal of this randomized treatment de-escalation study is to formally compare outcomes in HPV related oropharyngeal cancer tumours treated with a primary radiation therapy versus a primary surgical approach, to provide a high level of evidence to guide the selection of treatment options for a subsequent phase III trial The study will compare Progression free survival relative to historical controls for de-intensified primary radiation therapy [60 GY +/- chemotherapy] versus transoral surgery (TOS) and neck dissection [+/- adjuvant 50Gy radiation therapy] in patients with early T-stage HPV-positive squamous cell carcinoma of the oropharynx and to compare quality of life (QOL) profiles. The study will require a sample size of 120 patients randomized in a 1:1 ratio between the two arms. Arm 1 (radiotherapy +/1 chemotherapy) and Arm 2 (TOS) Patients will be followed for a total of 5 years

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society